Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Genentech’s Alecensa Joins The ALK Inhibitor Market

This article was originally published in The Pink Sheet Daily

Executive Summary

Alectinib will launch within two weeks for second-line ALK-positive non-small lung cancer at the price of $12,500 per month.


Related Content

Roche: Slow And Steady Wins The Race
Pfizer Expands Xalkori Labeling To New, Rare Lung Cancer Subtype
Novartis’ Zykadia Sets New “Breakthrough” Speed Record For NME Review
Pfizer’s Xalkori Joins The Six-Figure Oncology Drug Club


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts